King's College London
- Country
- 🇸🇪Sweden
- Ownership
- Private
- Established
- 1829-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://www.kcl.ac.uk
Clinical Trials
735
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (563 trials with phase data)• Click on a phase to view related trials
A Feasibility Study to Determine the Most Appropriate Digital Dietary Assessment Tool in Patients With Obesity Initiating GLP-1 Receptor Agonist Treatment
- Conditions
- Obese Patients
- First Posted Date
- 2025-09-26
- Last Posted Date
- 2025-09-26
- Lead Sponsor
- King's College London
- Target Recruit Count
- 50
- Registration Number
- NCT07194317
- Locations
- 🇬🇧
Guy's and St Thomas' NHS Trust, London, Southwark, United Kingdom
Safety and Efficacy of Aneurysms Treated With Endovascular Devices
- Conditions
- Brain AneurysmStrokeIntracranial Hemorrhages
- First Posted Date
- 2025-09-16
- Last Posted Date
- 2025-09-16
- Lead Sponsor
- King's College London
- Target Recruit Count
- 5000
- Registration Number
- NCT07175519
- Locations
- 🇬🇧
Kings College Hospital, London, London, United Kingdom
Measurement of Serum Inflammatory Markers in Patients Treatment-resistant Depression Given Psilocybin
- Conditions
- Depression - Major Depressive Disorder
- First Posted Date
- 2025-09-10
- Last Posted Date
- 2025-09-10
- Lead Sponsor
- King's College London
- Target Recruit Count
- 46
- Registration Number
- NCT07164755
- Locations
- 🇬🇧
King's College London Institute of Psychiatry, Psychology and Neuroscience, London, United Kingdom
A Longitudinal, Cohort Study Investigating the Impact of General Anaesthetic Caesarean Birth, With or Without ICU Admission, on Maternal Mental Health and Mother/Infant Bonding
- Conditions
- General Anaesthesia During Pregnancy
- First Posted Date
- 2025-08-11
- Last Posted Date
- 2025-08-11
- Lead Sponsor
- King's College London
- Target Recruit Count
- 500
- Registration Number
- NCT07115823
- Locations
- 🇬🇧
Faculty of Life Science and Medicine, London, United Kingdom
Real-time Molecular Diagnosis of Oral Precancer
- Conditions
- Oral CancerDysplasiaOral LesionsOral Pre-cancerMouth Cancer
- First Posted Date
- 2025-08-07
- Last Posted Date
- 2025-08-19
- Lead Sponsor
- King's College London
- Target Recruit Count
- 40
- Registration Number
- NCT07110623
- Locations
- 🇬🇧
Oral Clinical Research Unit, Guy's Hospital, London, Surrey, United Kingdom
- Prev
- 1
- 2
- 3
- 4
- 5
- 94
- Next
News
Inhaled Heparin Reduces COVID-19 Ventilation Risk by 50% in International Trial
A clinical trial involving nearly 500 COVID-19 patients across six countries found that inhaled heparin reduced the risk of requiring ventilation by half and significantly lowered mortality rates.
Nuclide Therapeutics Secures £5M to Advance ALDH1A1-Targeted Radiotheranostics for Therapy-Resistant Cancers
King's College London spin-out Nuclide Therapeutics has closed a £5 million investment round from Marathon Beteiligungs AG to advance radiotheranostic treatments for therapy-resistant cancers.
Nxera Pharma Advances Novel EP4 Antagonist HTL0039732 to Phase 2a Trial for Advanced Solid Tumors
Nxera Pharma and Cancer Research UK have dosed the first patient in a Phase 2a trial of HTL0039732, an oral EP4 antagonist immunotherapy for advanced solid tumors.
Genetic Testing Shows Promise for Faster IVF Success in Women Over 35, Pilot Study Finds
A pilot randomized controlled trial by King's College London found that preimplantation genetic testing for aneuploidy (PGT-A) resulted in a 72% cumulative live birth rate versus 52% in the control group among women aged 35-42.
Cyclophilin Inhibitor Shows Promise for Reversing Alcohol-Related Liver Fibrosis in Human Tissue Models
Researchers at King's College London demonstrated that cyclophilin inhibitors can reverse key features of alcohol-related liver disease by reducing fibrotic protein accumulation in human tissue models.
Japanese Researchers Begin Human Trials for Revolutionary Tooth Regeneration Drug
Japanese scientists have initiated clinical trials for a groundbreaking drug that could enable humans to regrow missing or damaged teeth by targeting the USAG-1 protein.
FDA Study Reveals Liver Safety Concerns with Low-Dose CBD in 5% of Healthy Adults
A new FDA randomized controlled trial found that 5% of healthy adults developed elevated liver enzymes after taking low-dose CBD (5 mg/kg body weight) for four weeks, with women appearing more vulnerable than men.
AI-Guided Drug Discovery Identifies Promising Cancer Treatment Combinations Using Existing Non-Cancer Medications
University of Cambridge researchers used GPT-4 to identify drug combinations that could treat cancer, finding that three of 12 AI-suggested combinations outperformed current breast cancer drugs in laboratory tests.
Safety Concerns Emerge for Gold-Based Cisplatin Mimics in Cancer Treatment Development
Researchers from King's College London and Jagannath University discovered that gold-based cisplatin mimics contain a mixture of potentially dangerous isomers rather than a pure compound as previously believed for over 60 years.
Mindfulness-Based Cognitive Therapy Shows Promise for Treatment-Resistant Depression
A new clinical trial published in Lancet Psychiatry demonstrates that mindfulness-based cognitive therapy (MBCT) significantly improves symptoms in patients with difficult-to-treat depression compared to standard care.